The investigation of SIGLEC15 as a potential target in cancer immunotherapy, highlighted by Wang’s insights (Wang et al., 2019; Sun et al., 2021), opens a promising pathway for advancing diagnostic and therapeutic approaches in COAD (Sun et al., 2021). This evidence concerns the gene SIGLEC15 and colon adenocarcinoma.